Therapies targeting the estrogen pathway in breast and endometrial cancer include tamoxifen, whose metabolites inhibit estrogen receptor activity, and aromatase inhibitors (AIs) such as anastrozole, letrozole, and exemestane which ultimately act by reducing circulating estrogen. This evidence concerns the gene CYP19A1 and endometrial cancer.